Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation

PURPOSE AND DESIGN: Mechanism(s) by which the multi-kinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal and pancreatic adenocarcinoma cells have been defined. RESULTS: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic f...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Zhang, Guo, Park, Margaret A., Mitchell, Clint, Hamed, Hossein, Rahmani, Mohammed, Martin, Aditi Pandya, Curiel, David T., Yacoub, Adly, Graf, Martin, Lee, Ray, Roberts, John D., Fisher, Paul B., Grant, Steven, Dent, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2561272/
https://ncbi.nlm.nih.gov/pubmed/18765530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0469
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller